Am­gen lines up new AI biotech part­ner in PostEra to de­vel­op small mol­e­cule med­i­cines

Am­gen is en­list­ing AI start­up PostEra for a drug dis­cov­ery deal for five small mol­e­cule pro­grams, PostEra an­nounced Thurs­day morn­ing.

Few de­tails about the col­lab­o­ra­tion were made avail­able. PostEra CEO Aaron Mor­ris de­clined to com­ment on the deal val­ue in an in­ter­view with End­points News. How­ev­er, he de­scribed it as the “most mean­ing­ful part­ner­ship we’ve done to date,” and added that it brings the to­tal deal val­ue PostEra has closed to over $1 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER